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Cigarette smoking is highly addictive, and modern genetic research has identified robust
genetic influences on nicotine dependence. An important step in translating these genetic
findings is to identify the genetic factors affecting smoking cessation in order to enhance
current smoking cessation treatments. We review the significance of variants in the
nicotinic receptor gene cluster (CHRNA5eCHRNA3eCHRNB4) in the prediction of smoking
quantity, smoking cessation, and response to cessation medication in multiple studies of
smoking cessation. Three common haplotypes (low-risk, intermediate-risk, and high-risk)
in the CHRNA5eCHRNA3eCHRNB4 region are defined by rs16969968 and rs680244. The
genetic variants in the CHRNA5eCHRNA3eCHRNB4 region that predict nicotine dependence
also predicted a later age of smoking cessation in a community-based sample. In a smoking
cessation trial, these variants predicted abstinence at the end of treatment in individuals
receiving placebo medication, but not among individuals receiving active medication.
Pharmacological treatments moderate the genetic risk in affecting cessation success.
These pharmacogenetic interactions have been reproduced by a recent meta-analysis of
smoking cessation trials. The number needed to treat was four for smokers with the high-
risk haplotype, seven for smokers with the intermediate-risk haplotype, and > 1000 for
smokers with the low-risk haplotype. The wide variation in number needed to treat be-
tween smokers with different haplotypes supports the notion that personalized smoking
cessation intervention based upon genotype could meaningfully increase the efficiency of
such treatment. In summary, variants in the CHRNA5eCHRNA3eCHRNB4 region identify
individuals at increased risk of cessation failure, and this increased risk can be ameliorated
by cessation pharmacotherapy.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
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a critical step in understanding the biology of nicotine
dependence, enhancing prediction of prognosis and treat-
ment outcomes, and informing more effective cessation
treatments.
Genomic research can lead to personalized medicine [7].
Growing research in understanding human genomes and
identifying specific genetic markers for a disease will not only
lead to improved understanding of the biology underlying the
disease, but also improved clinical care. In clinical practice, it
is common for different patients to show different efficacy or
side effects with the same medication regimen, such as
tamoxifen for breast cancer risk reduction in patients with
selected biomarkers [8]. Increasing evidence suggests that the
risk/benefit ratio of the medication may vary with a person’s
genetic makeup. The goal of personalized medicine is to tailor
treatments for each patient to maximize benefits and mini-
mize side effects.2. Genetics of nicotine dependence
Multiple, recent, large genetic meta-analyses based on tens of
thousands of individuals of European descent have confirmed
the association of 15q25.1 with smoking heaviness, defined by
cigarettes per day [9e12], with the most robust associations
being reported for rs16969968 and rs1051730; two highly corre-
lated variants (p < 5.57  1072) [11]. In the CHRNA5eCHR-
NA3eCHRNB4 region, at least two independent signals have
been identified [10,13]. The first signal tagged by rs16969968, a
variant that results in an amino acid change in the a5 nicotinic
cholinergic receptor (CHRNA5), alters nicotinic receptor
conductance in vitro [14,15]. A second, distinct signal tagged by
rs680244 is associated with variability in CHRNA5mRNA levels
[16]. Individuals of European descent have one of the threeFig. 1 e CHRNA5 predicts smoking cessation and response to m
haplotypes. H1 [ G_C (20.8%); H2 [ G_T (43.7%); H3 [ A_C (35.common haplotypes in the region spanning CHRNA5 and the 30
endofCHRNA3 [13],which canbedefinedby these twovariants:
rs16969968 and rs680244 [16]. These threehaplotypes represent
different risk levels of nicotine dependence: low-risk (H1, 21%),
intermediate-risk (H2, 44%), andhigh-risk (H3, 36%)haplotypes.3. Genetics of smoking cessation
The CHRNA5eCHRNA3eCHRNB4 variants have been less
consistently associated with cessation outcomes than with
smoking heaviness measures. Five studies have shown an
association between the CHRNA5eCHRNA3eCHRNB4 region
and successful smoking cessation [17e21]. All five found that
the same genetic risk variants that contribute to smoking
heaviness and nicotine dependence also predicted smoking
cessation. Yet, other studies failed to confirm this association
[22e24]. Uhl et al [24], in a genome-wide association of three
treatment cohorts, did not identify any nicotinic receptor
genes as predictors of prospectively measured smoking
cessation. One large genome-wide association meta-analysis
that strongly supported the association between 15q25.1 and
smoking heaviness reported a modest association with cur-
rent versus former smoking as a measure of smoking cessa-
tion below genome-wide level of significance [11]. Variations
in study design (with or without a placebo group), ascertain-
ment, and definitions of smoking cessation (time to relapse,
abstinence, or the contrast of former vs. current smoker) may
explain these inconsistent findings.
3.1. CHRNA5eCHRNA3eCHRNB4 genetic variants
predict age of smoking cessation
CHRNA5eCHRNA3eCHRNB4 haplotypes were associated with
age of self-reported smoking cessation in a community-basededication: number needed to treat (NNT) varies with
5%). NNT [ number of patients to treat for one to benefit.
j o u r n a l o f f o o d and d r u g an a l y s i s 2 1 ( 2 0 1 3 ) s 8 7es 9 0 S89sample [25]. Compared to the low-risk haplotype (H1), the
high-risk haplotype (H3) was associated with a later quitting
age. The median age of smoking cessation was 57 years for
those with haplotype H3, and 55 years for those with haplo-
types H2 and H1. This study showed that the genetic variants
in the chromosome 15q25 region that predicted heavy smok-
ing and nicotine dependence also predicted a later age of
smoking cessation in a large community-based sample. Those
with the high-risk genetic variants quit later than those at low
genetic risk, manifested as a 2-year delay in median quit age.
3.2. CHRNA5eCHRNA3eCHRNB4 genetic variants
predict smoking relapse and response to medication
In a large smoking cessation trial of smokers receiving
cessation counseling with placebo medication, the high-risk
haplotype (H3) that was associated with heavy smoking pre-
dicted failed abstinence in comparison to the low-risk haplo-
type (H1) [25]. Pharmacological treatment significantly
increased the likelihood of abstinence in individuals with the
high-risk haplotype (H3) but exerted little effect in individuals
with the low-risk haplotype (H1). This was reflected by a sig-
nificant interaction between treatment (placebo vs. active
treatment) and haplotypes (Fig. 1). Across the active phar-
macological treatment conditions, these genetic variants do
not predict abstinence, and this reduced genetic effect with
pharmacological treatments suggests that cessation treat-
ments differ in effectiveness across the haplotypes and most
stronglymitigates the genetic risks for cessation difficulty [26].
A recent meta-analysis of the Pharmacogenetics of Nicotine
Addiction Treatment (PNAT) Consortium reported a similar
pharmacogenetic interaction, in that patient responses to
nicotine replacement therapy (NRT) were moderated by
CHRNA5 genetic variants [27].
Medication efficacy is often represented by the number
needed to treat (NNT) [25]. The NNT is seven when computed
across all individuals regardless of their haplotype status,
supporting the established effect of pharmacotherapy. How-
ever, the NNT varies widely, depending on the individual’s
haplotype. Based on their absolute risks, the NNT is four for
smokers with the high-risk haplotype, seven for smokers with
the intermediate-risk haplotype, and > 1000 for smokers with
the low-risk haplotype. An NNT of four is an impressive
finding, compared to the NNTs of many existing pharmaco-
therapies [28e30]. Thewidevariation inNNTbetweensmokers
with different haplotypes supports the notion that personal-
ized smoking cessation intervention based upon genotype
could meaningfully increase the efficiency of such treatment.4. Conclusions
Multiple studies have underscored the relation between the
targeted haplotypes, nicotine dependence, and smoking
cessation. There is a significant interaction among these
CHRNA5eCHRNA3eCHRNB4 haplotypes and treatment on
cessation success, and this reveals that cessation treatment
effectiveness is modulated by the haplotypes. These findings
strengthen the case for the development and rigorous testing
of treatments that target patients with different genetic riskprofiles based on the chromosome 15q25 region that includes
the genes encoding the nicotinic receptor subunits. Those
with the high/intermediate-risk haplotypes appear more bio-
logically predisposed to having difficulty quitting without
pharmacological treatment, and this risk may be ameliorated
by effective pharmacological treatment. Smoking cessation
pharmacotherapy such as NRT, bupropion, and varenicline is
moderately effective, yet it does have side effects. Identifying
genes related to responsiveness to pharmacological treatment
for nicotine addiction may lead to improved treatment algo-
rithms that further the promise of personalized medicine [31].Disclosure of conflicts of interest
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